

Tascenso (fingolimod)
Effective 02/01/2023

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

Overview

Tascenso ODT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg.

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Tascenso ODT excluding when the product is obtained as samples or via manufacturer's patient assistance program

OR

Approval will be granted if the member meets all following criteria and documentation has been submitted:

1. The member is at least 10 years of age
2. The member has a diagnosis of ONE of the following forms of Multiple Sclerosis (MS):
 - a. Clinically isolated syndrome
 - b. Relapsing-remitting disease
 - c. Active secondary progressive disease
3. The member weighs at least 40kg
4. The prescriber is a neurologist or neurology consult notes are provided
5. The member has had inadequate response, adverse reaction, or contraindication to Gilenya (fingolimod) capsules

Continuation of Therapy

Reauthorization may be granted with provider attestation that member is experiencing disease stability or improvement while receiving the medication.

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months.
2. The following quantity limits apply:

Tascenso ODT	60 capsules per 30 days
--------------	-------------------------

References

1. Tascenso ODT [package insert]. San Jose, CA: Handa Neuroscience, LLC; December 2021.

Review History

01/11/2023 – Created and Reviewed at January P&T. Effective 02/01/23

